

Faculty and Planner Disclosures

Disclosure Statement of Need

The need for this activity has been determined based on identifying professional practice gaps, as well as review of previous course evaluations and member surveys. The educational content was developed based on current issues and topic trends provided by the American Academy of Sleep Medicine (AASM) leadership and membership.

Disclosure Statement

The American Academy of Sleep Medicine (AASM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. As an accredited provider, the AASM must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. Prior to the activity, all speakers must disclose to their audience that the individual has no relevant financial relationship(s) with an ineligible company OR has any relevant financial relationships with an ineligible company.

The ACCME Standards for Commercial Support require accredited CME providers to resolve all identified potential conflicts of interest with any individual in a position to influence and/or control the content of CME activities prior to the education activity being delivered to learners.

Resolution of Conflicts of Interest (COI)

AASM has implemented mechanisms to identify and mitigate conflicts of interest for all individuals in a position to control content, prior to the planning and implementation of these CME activities. Course Chair(s) reviewed the COI declarations and are satisfied that no commercial bias exists. All conflict-of-interest disclosures are provided to participants prior to start of the activity.

Insomnia Series Part 3: Pharmacotherapy Planners:

- Jenny Bogda has no relevant financial relationships with ineligible companies to disclose.
- Kristin Cuzzone has no relevant financial relationships with ineligible companies to disclose.

Insomnia Series Part 3: Pharmacotherapy Speakers:

- Mojdeh Heavner, PharmD has no relevant financial relationships with ineligible companies to disclose.